Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Venquis inflammatory disease CIPD program
- Development stage
- Preclinical
- Lead developer
- Venquis Therapeutics
- Modality
- Targeted Protein Degraders (TPDs) → Small Molecules
01
Overview
Venquis Therapeutics is developing an undisclosed small molecule protein degrader for the treatment of inflammatory diseases. This program utilizes the company's proprietary Chemically Induced Protein Degrader (CIPD) platform, which is designed to create direct protein degraders. Unlike traditional PROTACs or molecular glues, CIPD molecules are intended to be mutant-selective, sparing wild-type proteins to potentially improve the safety profile and reduce off-target toxicity. The program is currently in the preclinical stage of development.
- Other names
- Venquis inflammatory disease degraderUndisclosed target (inflammatory disease)Venquis Therapeutics-undisclosed-small molecule degrader-inflammatory disease
Beyond the preview
Go deeper on Venquis inflammatory disease CIPD program.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Venquis inflammatory disease CIPD program.